目的 观察舒利迭(50/500)对激素抵抗型哮喘患者的疗效。方法 将36例激素抵抗型支气管哮喘患者随机分为舒利迭治疗组和泼尼松治疗组；另选18名激素敏感型哮喘患者为对照组。泼尼松治疗组口服泼尼松治疗，舒利迭治疗组及对照组均给予舒利迭(50/500)治疗，各组氨茶碱治疗相同。记录治疗前、后患者的肺功能，并检测血清IFN-γ和IL-4的量。结果 舒利迭治疗组的总有效率高于泼尼松治疗组，疗效差异显著（P＜0.05)，且两组疗效均低于对照组，差异显著(P＜0.50)；舒利迭治疗组的IFN-γ高于泼尼松治疗组，但差异不显著(P＞0.05)；舒利迭治疗组的IL-4低于泼尼松治疗组，且差异显著(P＜0.05)。结论 应用舒利迭(50/500)治疗激素抵抗型哮喘，能一定程度改善肺功能，使用安全，值得在临床推广；且激素抵抗型哮喘的发病机制可能与IL-4升高有关。

Objective To investigate in effects of treatment using seretide on patients with glucocoticoid resistant asthma. Methods 36 Patients with glucocoticoid resistant asthma were randomly divided into seretide (50/500) treatment and prednisone treatment groups. And 18 patients with glucocoticoid sensitive asthma were control groups. The control group was given conventional treatment, the seretide (50/500) treatment group was given seretide (50/500) on the basis of conventional treatment. The parameters of lung function test and IFN-γ and IL-4 were measured before and after treatment. Results The efficient of the seretide (50/500) treatment group significantly higher than that of the prednisone treatment group. Efficacy difference between the two groups was significant (P＜0.05)；And two groups significantly lower than that control group, efficacy difference was significant (P＜0.05)；IFN-γ of the seretide (50/500) treatment group was higher than that of the prednisone treatment group. But efficacy difference between the two groups was not significant (P＞0.05)；IL-4 of the seretide (50/500) treatment group was significantly higher than that of the prednisone treatment group. Efficacy difference between the two groups was significant (P＜0.05)；Seretide had no obvious side effects. Conclusion Application of seretide (50/500) in the treatment of glucocoticoid resistant asthma can significantly improve blood gas indicators. The use is safe. It is worth promoting in the clinic. And the mechanism of glucocoticoid resistant asthma maybe relat to IL-4.